Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of Evolocumab on Coronary Plaque Composition.
Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJP, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Honda S, Shishikura D, Scherer DJ, Borgman M, Brennan DM, Wolski K, Nissen SE. Nicholls SJ, et al. Among authors: kassahun h. J Am Coll Cardiol. 2018 Oct 23;72(17):2012-2021. doi: 10.1016/j.jacc.2018.06.078. J Am Coll Cardiol. 2018. PMID: 30336824 Free article. Clinical Trial.
Relationship between changes in coronary atherosclerotic plaque burden measured by intravascular ultrasound and cardiovascular disease outcomes: a systematic literature review.
Forbes C, Quek RG, Deshpande S, Worthy G, Ross J, Kleijnen J, Gandra SR, Kassahun H, Wong ND, Nicholls SJ. Forbes C, et al. Among authors: kassahun h. Curr Med Res Opin. 2016 Jun;32(6):1143-50. doi: 10.1185/03007995.2016.1162775. Epub 2016 Mar 17. Curr Med Res Opin. 2016. PMID: 26949994 Review.
Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).
Puri R, Nissen SE, Somaratne R, Cho L, Kastelein JJ, Ballantyne CM, Koenig W, Anderson TJ, Yang J, Kassahun H, Wasserman SM, Scott R, Borgman M, Nicholls SJ. Puri R, et al. Among authors: kassahun h. Am Heart J. 2016 Jun;176:83-92. doi: 10.1016/j.ahj.2016.01.019. Epub 2016 Feb 17. Am Heart J. 2016. PMID: 27264224 Clinical Trial.
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE. Nicholls SJ, et al. Among authors: kassahun h. JAMA. 2016 Dec 13;316(22):2373-2384. doi: 10.1001/jama.2016.16951. JAMA. 2016. PMID: 27846344 Clinical Trial.
Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.
Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H, Ruzza A, Ma Y, Somaratne R, Raal FJ. Koren MJ, et al. Among authors: kassahun h. JAMA Cardiol. 2017 Jun 1;2(6):598-607. doi: 10.1001/jamacardio.2017.0747. JAMA Cardiol. 2017. PMID: 28291870 Free PMC article.
Evolocumab: Considerations for the Management of Hyperlipidemia.
Wiggins BS, Senfield J, Kassahun H, Lira A, Somaratne R. Wiggins BS, et al. Among authors: kassahun h. Curr Atheroscler Rep. 2018 Mar 6;20(4):17. doi: 10.1007/s11883-018-0720-3. Curr Atheroscler Rep. 2018. PMID: 29511875 Review.
Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.
Stiekema LCA, Stroes ESG, Verweij SL, Kassahun H, Chen L, Wasserman SM, Sabatine MS, Mani V, Fayad ZA. Stiekema LCA, et al. Among authors: kassahun h. Eur Heart J. 2019 Sep 1;40(33):2775-2781. doi: 10.1093/eurheartj/ehy862. Eur Heart J. 2019. PMID: 30561610 Free PMC article. Clinical Trial.
58 results